31
Participants
Start Date
November 30, 1998
Primary Completion Date
April 30, 2002
Study Completion Date
November 30, 2012
tositumomab and iodine I 131 tositumomab
Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
University of Nebraska Medical Center, Omaha
Collaborators (1)
National Cancer Institute (NCI)
NIH
Coulter Pharmaceutical, Inc.
INDUSTRY
University of Nebraska
OTHER